No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
J. B. Chemicals & Pharmaceuticals Limited, established in 1976 and based in Mumbai, India, operates as a global pharmaceutical enterprise. The company is engaged in the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical formulations, herbal treatments, and active pharmaceutical ingredients (APIs) for both domestic and international markets. Its API range features compounds such as diclofenac sodium, nifedipine, and ciprofloxacin. Beyond its own product lines, J. B. Chemicals provides comprehensive contract manufacturing services for various dosage forms, including tablets, injectables, gels, creams, capsules, and a specialized array of lozenges. Additionally, the company offers a suite of contrast media products essential for medical imaging, such as X-ray, MRI, and ultrasound. Their extensive portfolio addresses critical therapeutic areas, including but not limited to gastroenterology, anti-infectives, cardiovascular health, diabetes, respiratory conditions, pain management, and dermatology.
www.jbpharma.comNo one on the platform currently holds JBCHEPHARM.BO.
No tracked institution reports a position in JBCHEPHARM.BO as of their last filing.
No one on the platform has traded JBCHEPHARM.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 17.0% | 16.9% | 15.5% | — | — | — |
| Rev. Growth % | 7.4% | 15.5% | ||||
| Profit Margin % | 17.1% | 15.9% | 15.3% | |||
| Free Cash Flow Margin % | 15.1% | 5.0% | 6.8% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $46.4B | +8.3% | $56.20 | $49.46–$62.28 | — | 7 |
| 2028 | $55.5B | +19.7% | $75.70 | $70.25–$84.12 | — | 7 |
| 2029 | $57.1B | +2.8% | $93.60 | $87.81–$103.05 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $13.55 | $13.55 | +0.0% |
| 2026-05-11 | $9.90 | $7.70 | -22.2% |
| 2026-02-02 | $12.30 | $12.70 | +3.3% |
| 2025-11-11 | $12.90 | $13.30 | +3.1% |
| 2025-07-30 | $13.60 | $13.70 | +0.7% |
| 2025-05-14 | $8.30 | $9.30 | +12.0% |
| 2025-02-04 | $10.20 | $10.40 | +2.0% |
| 2024-11-06 | $10.80 | $11.00 | +1.9% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| JBCHEPHARM.BOJ. B. Chemicals & Pharmaceuticals Limited | $2412.25 | -3.70% | $387.3B | — |
| AJANTPHARM.BOAjanta Pharma Limited | $3506.25 | -0.87% | $437.4B | — |
| AUROPHARMA.NSAurobindo Pharma Limited | $1660.00 | -1.18% | $955.1B | — |
| BALAXI.NSBalaxi Pharmaceuticals Limited | $23.12 | -1.15% | $1.3B | — |
| BBTC.BOThe Bombay Burmah Trading Corporation, Limited |
| $1416.60 |
| -0.45% |
| $99.3B |
| — |
| CIPLA.BOCipla Limited | $1361.00 | -0.29% | $1.11T | — |
| ERIS.NSEris Lifesciences Limited | $1310.10 | -3.35% | $181.6B | — |
Source: Financial Modeling Prep · peers by sector/industry